Skip to content
Disclosery

TAKEDA PHARMACEUTICAL CO LTD

Follow

13F filer, CIK 1395064, Tokyo, Japan

TAKEDA PHARMACEUTICAL CO LTD reported $232,311,238 across 13 holdings for the quarter ended 2024-06-30, in a 13F-HR filed 2025-02-13. Its ten largest share positions make up 99.63% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001395064-25-000028

Period
2024-06-30
Reported value
$232M
Holdings
13
Top 10 weight
99.63%
New
0
Sold out
2

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PHATreduced-1,596,154-$16.4M
STTKreduced-985,442-$3.8M
DAWNexited-85,840-$1.42M
RANIreduced-123,507-$469K
AEROVATE THERAPEUTICS INCexited-13,580-$402K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2024

Share positions as resolved from 13F-HR 0001395064-25-000028, largest first. % of portfolio is the value over $232,311,238, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
DNLIDENALI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 4,214,559 shares; 2024Q1: 4,214,559 shares; 2024Q2: 4,214,559 shares 4,214,559$97.9M42.13%0Timeline
HILLEVAX INCHILLEVAX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 6,724,000 shares; 2024Q1: 6,724,000 shares; 2024Q2: 6,724,000 shares 6,724,000$97.2M41.85%0
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 7,459,286 shares; 2024Q1: 3,153,217 shares; 2024Q2: 1,557,063 shares 1,557,063$16M6.9%-1,596,154Timeline
WVEWAVE LIFE SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,346,892 shares; 2024Q1: 1,346,892 shares; 2024Q2: 1,346,892 shares 1,346,892$6.72M2.89%0Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 7,531,996 shares; 2024Q1: 7,531,996 shares; 2024Q2: 7,531,996 shares 7,531,996$5.79M2.49%0Timeline
TURNSTONE BIOLOGICS CORPTURNSTONE BIOLOGICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 895,824 shares; 2024Q1: 895,824 shares; 2024Q2: 895,824 shares 895,824$2.35M1.01%0
STTKSHATTUCK LABS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 2,090,858 shares; 2024Q1: 1,501,061 shares; 2024Q2: 515,619 shares 515,619$1.99M0.86%-985,442Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,475,121 shares; 2024Q1: 1,475,121 shares; 2024Q2: 1,475,121 shares 1,475,121$1.4M0.6%0Timeline
EQEQUILLIUM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,824,977 shares; 2024Q1: 1,824,977 shares; 2024Q2: 1,824,977 shares 1,824,977$1.26M0.54%0Timeline
RANIRANI THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 338,679 shares; 2024Q1: 338,679 shares; 2024Q2: 215,172 shares 215,172$818K0.35%-123,507Timeline
AMWLAMERICAN WELL CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,554,669 shares; 2024Q1: 1,554,669 shares; 2024Q2: 1,554,669 shares 1,554,669$505K0.22%0Timeline
AKILI INCAKILI INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 738,819 shares; 2024Q1: 738,819 shares; 2024Q2: 738,819 shares 738,819$321K0.14%0
LABSTANDARD BIOTOOLS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 16,515 shares; 2024Q1: 16,515 shares; 2024Q2: 16,515 shares 16,515$29.2K0.01%0Timeline

Sold out in Q2 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
DAWNDAY ONE BIOPHARMACEUTICALS I85,840$1.42Mshares
AEROVATE THERAPEUTICS INCAEROVATE THERAPEUTICS INC13,580$402Kshares

How Q2 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001395064-25-000028 base2025-02-13acceptance time not in the bulk data set